| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $34,400 | 1 | 4 |
Sells | $864,004 | 25 | 96 |
| Bjork Elisabeth | director | 1 | $34,400 | 0 | $0 | $34,400 |
| Schwartz Jonathan David | See Remarks | 0 | $0 | 1 | $7,592 | $-7,592 |
| Militello John | See Remarks | 0 | $0 | 5 | $23,683 | $-23,683 |
| Chaudhuri Sarbani | See Remarks | 0 | $0 | 2 | $84,190 | $-84,190 |
| Stevens Christopher James | Chief Operating Officer | 0 | $0 | 1 | $128,266 | $-128,266 |
| Shah Gaurav | CEO | 0 | $0 | 8 | $285,667 | $-285,667 |
| Wilson Martin | General Counsel | 0 | $0 | 8 | $334,607 | $-334,607 |
Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs. It is currently progressing three ex vivo lentiviral vector therapies aimed at specific genetic conditions: Fanconi anemia, characterized by a bone marrow defect that hinders blood cell production; leukocyte adhesion deficiency-I, an inherited disorder resulting in a compromised …
Over the last 12 months, insiders at Rocket Pharmaceuticals, Inc. have bought $34,400 and sold $864,004 worth of Rocket Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Rocket Pharmaceuticals, Inc. have bought $6.85M and sold $3.59M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Bjork Elisabeth (director) — $34,400.
The last purchase of 10,000 shares for transaction amount of $34,400 was made by Bjork Elisabeth (director) on 2026‑01‑02.
| 2026-09-11 | Sale | Wilson Martin | General Counsel | 75,364 0.0678% | $3.40 | $256,464 | -23.58% | |
| 2026-08-18 | Sale | Shah Gaurav | CEO | 2,293 0.0021% | $3.38 | $7,753 | -21.26% | |
| 2026-08-18 | Sale | Wilson Martin | General Counsel | 631 0.0006% | $3.38 | $2,133 | -21.26% | |
| 2026-08-13 | Sale | Shah Gaurav | CEO | 2,837 0.0025% | $3.38 | $9,592 | -19.46% | |
| 2026-08-13 | Sale | Wilson Martin | General Counsel | 3,493 0.0031% | $3.38 | $11,810 | -19.46% | |
| 2026-08-11 | Sale | Stevens Christopher James | Chief Operating Officer | 36,658 0.0336% | $3.50 | $128,266 | -13.71% | |
| 2026-08-11 | Sale | Chaudhuri Sarbani | See Remarks | 4,701 0.0043% | $3.50 | $16,449 | -13.71% | |
| 2026-05-21 | Sale | Shah Gaurav | CEO | 55,684 0.0506% | $3.09 | $171,841 | +5.31% | |
| 2026-05-19 | Sale | Shah Gaurav | CEO | 2,409 0.0023% | $3.01 | $7,261 | +11.64% | |
| 2026-05-19 | Sale | Wilson Martin | General Counsel | 662 0.0006% | $3.01 | $1,995 | +11.64% | |
| 2026-05-19 | Sale | Militello John | See Remarks | 384 0.0004% | $3.01 | $1,157 | +11.64% | |
| 2026-05-13 | Sale | Shah Gaurav | CEO | 2,728 0.0025% | $3.61 | $9,837 | -9.72% | |
| 2026-05-13 | Sale | Wilson Martin | General Counsel | 3,361 0.0031% | $3.61 | $12,120 | -9.72% | |
| 2026-05-13 | Sale | Militello John | See Remarks | 855 0.0008% | $3.61 | $3,083 | -9.72% | |
| 2026-05-07 | Sale | Chaudhuri Sarbani | See Remarks | 17,650 0.0169% | $3.84 | $67,741 | -10.76% | |
| 2026-02-18 | Sale | Shah Gaurav | CEO | 5,990 0.0054% | $3.34 | $19,995 | +0.58% | |
| 2026-02-18 | Sale | Wilson Martin | General Counsel | 1,376 0.0012% | $3.34 | $4,593 | +0.58% | |
| 2026-02-18 | Sale | Militello John | See Remarks | 1,157 0.001% | $3.34 | $3,862 | +0.58% | |
| 2026-02-13 | Sale | Shah Gaurav | CEO | 12,279 0.0115% | $3.31 | $40,668 | +6.12% | |
| 2026-02-13 | Sale | Wilson Martin | General Counsel | 12,253 0.0115% | $3.31 | $40,582 | +6.12% |
| Shah Gaurav | CEO | 1056594 0.9625% | $2.65M | 2 | 21 | <0.0001% |
| Bjork Elisabeth | director | 50000 0.0455% | $125,500.00 | 2 | 0 | +4.22% |
| WONG RODERICK | director | 17628567 16.0589% | $44.25M | 1 | 0 | +5.66% |
| RTW INVESTMENTS, LP | 15460119 14.0835% | $38.8M | 3 | 1 | <0.0001% | |
| DEVON PARK BIOVENTURES LP | 10 percent owner | 3243709 2.9549% | $8.14M | 1 | 0 | +28.2% |
| Kantesaria Devang | 10 percent owner | 3243709 2.9549% | $8.14M | 1 | 0 | +28.2% |
| RHO VENTURES IV QP LP | 10 percent owner | 2870584 2.615% | $7.21M | 1 | 0 | +28.2% |
| KARABELAS ARGERIS N | 2277139 2.0744% | $5.72M | 1 | 0 | +28.2% | |
| CARE CAPITAL II LLC | 10 percent owner | 2277139 2.0744% | $5.72M | 1 | 0 | +28.2% |
| MedImmune Ventures, Inc. | 10 percent owner | 1917906 1.7471% | $4.81M | 1 | 0 | +28.2% |
| Pitango Venture Capital Principals Fund IV, L.P. | 10 percent owner | 1292584 1.1775% | $3.24M | 1 | 0 | +28.2% |
| Patel Kinnari | See Remarks | 441927 0.4026% | $1.11M | 3 | 10 | +84.02% |
| SOUTHWELL DAVID P | director | 114784 0.1046% | $288,107.84 | 1 | 5 | +4.41% |
| CARROLL J MARTIN | director | 10000 0.0091% | $25,100.00 | 1 | 0 |
$60,836,085 | 69 | 0.45% | $255.44M | |
$64,733,831 | 40 | 5.69% | $299.32M | |
$140,595,157 | 34 | 17.93% | $301.23M | |
$109,019,806 | 28 | 7.37% | $263.86M | |
$2,516,932 | 19 | -15.78% | $252.7M |
| Increased Positions | 91 | +42.13% | 14M | +14.51% |
| Decreased Positions | 96 | -44.44% | 20M | -20.71% |
| New Positions | 31 | New | 3M | New |
| Sold Out Positions | 26 | Sold Out | 2M | Sold Out |
| Total Postitions | 211 | -2.31% | 91M | -6.2% |
| Rtw Investments, Lp | $61,200.00 | 16.38% | 17.69M | 0 | 0% | 2025-09-30 |
| Maverick Capital Ltd | $29,300.00 | 7.84% | 8.47M | +104,531 | +1.25% | 2025-09-30 |
| Blackrock, Inc. | $24,616.00 | 6.59% | 7.11M | -314,305 | -4.23% | 2025-09-30 |
| Vanguard Group Inc | $23,847.00 | 6.38% | 6.89M | +769,743 | +12.57% | 2025-09-30 |
| Mpm Bioimpact Llc | $13,506.00 | 3.61% | 3.9M | +300 | +<0.01% | 2025-09-30 |
| Suvretta Capital Management, Llc | $13,298.00 | 3.56% | 3.84M | -300,000 | -7.24% | 2025-09-30 |
| Morgan Stanley | $12,619.00 | 3.38% | 3.65M | +478,003 | +15.08% | 2025-09-30 |
| Millennium Management Llc | $12,354.00 | 3.31% | 3.57M | +1M | +52.01% | 2025-09-30 |
| Monaco Asset Management Sam | $10,007.00 | 2.68% | 2.89M | +2M | +538.8% | 2025-09-30 |
| Newtyn Management, Llc | $8,660.00 | 2.32% | 2.5M | +502,863 | +25.14% | 2025-09-30 |